Sirtex Medical 1H 2017 Half Year Results

Sirtex Medical reported half-year results for the period ended December 31, 2016, with global dose sales growth of 5.6% despite challenging market conditions in the interventional oncology sector. The company achieved constant currency EBITDA of $33.6 million and announced launch of the SIRCCA clinical study for intrahepatic cholangiocarcinoma treatment. SIR-Spheres, the company's flagship product, remains early in market penetration at approximately 2%.